Fei Yu-Lin, Zhao Zhen-Long, Wei Ying, Peng Li-Li, Li Yan, Wu Jie, Cao Shi-Liang, Yu Na, Zhao Han-Xiao, Cai Wen-Jia, Yu Ming-An
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China.
Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11873-x.
Microwave ablation (MWA) has demonstrated short-term efficacy comparable to surgical resection (SR) for papillary thyroid carcinoma (PTC), but long-term data are limited.
To compare the long-term efficacy and safety of MWA versus SR in preoperative T1N0M0 PTC.
This single-center retrospective study included 792 patients with preoperative T1N0M0 PTC treated with MWA or SR from January 2016 to June 2019. Propensity score matching (PSM) balanced baseline characteristics between the MWA and SR groups, while inverse probability of treatment weighting (IPTW) was used for subgroup analyses between the MWA and total thyroidectomy (TT) or lobectomy (LT) groups. Primary outcomes were disease progression-free survival (DFS), thyroid recurrence-free survival (TRFS), lymph node recurrence-free survival (LRFS), and complication rates. Secondary outcomes were treatment variables, ablation zone volume reduction and disappearance rates.
Following PSM, 464 patients (median age 41 years; 343 females) were followed for a median of 69 months. No significant difference in DFS was observed between the MWA and SR groups. LRFS did not significantly differ between the two groups. TRFS was lower in the MWA group than in the SR group and the TT subgroup, but not different from the LT subgroup. The MWA group had fewer complications, with permanent hoarseness only in the SR group. MWA also resulted in shorter incisions, reduced operative and hospitalization times.
MWA offers comparable long-term efficacy to surgery for preoperative T1N0M0 PTC, with fewer complications.
Question What are the long-term outcomes of MWA compared to surgery for preoperative T1N0M0 papillary thyroid carcinoma? Findings Over a median follow-up of 69 months, the MWA group showed comparable disease-free survival but a lower complication rate than the SR group. Clinical relevance This study provides long-term comparative data on MWA and surgery for preoperative T1N0M0 papillary thyroid carcinoma, offering valuable insights for clinical decision-making.
对于甲状腺乳头状癌(PTC),微波消融(MWA)已显示出与手术切除(SR)相当的短期疗效,但长期数据有限。
比较MWA与SR在术前T1N0M0 PTC中的长期疗效和安全性。
这项单中心回顾性研究纳入了2016年1月至2019年6月期间接受MWA或SR治疗的792例术前T1N0M0 PTC患者。倾向评分匹配(PSM)平衡了MWA组和SR组之间的基线特征,而治疗权重逆概率(IPTW)用于MWA组与全甲状腺切除术(TT)或甲状腺叶切除术(LT)组之间的亚组分析。主要结局为无疾病进展生存期(DFS)、无甲状腺复发生存期(TRFS)、无淋巴结复发生存期(LRFS)和并发症发生率。次要结局为治疗变量、消融区体积缩小率和消失率。
PSM后,464例患者(中位年龄41岁;343例女性)接受了中位69个月的随访。MWA组和SR组之间在DFS方面未观察到显著差异。两组之间的LRFS无显著差异。MWA组的TRFS低于SR组和TT亚组,但与LT亚组无差异。MWA组的并发症较少,仅SR组出现永久性声音嘶哑。MWA还导致切口更短,手术和住院时间缩短。
对于术前T1N0M0 PTC,MWA提供了与手术相当的长期疗效,且并发症更少。
问题与术前T1N0M0甲状腺乳头状癌手术相比,MWA的长期结局如何?研究结果在中位随访69个月期间,MWA组显示出可比的无病生存期,但并发症发生率低于SR组。临床意义本研究提供了术前T1N0M0甲状腺乳头状癌MWA与手术的长期比较数据,为临床决策提供了有价值的见解。